GTC Biotherapeutics Lands $7,000,000 New Financing

  • Feed Type
  • Date
    6/16/2010
  • Company Name
    GTC Biotherapeutics
  • Mailing Address
    175 Crossing Blvd. Framingham, MA 01702
  • Company Description
    GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures.
  • Website
    http://www.transgenics.com
  • Transaction Type
    Debt
  • Transaction Amount
    $7,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.